Matthew Boente

5.7k total citations · 2 hit papers
54 papers, 3.7k citations indexed

About

Matthew Boente is a scholar working on Reproductive Medicine, Oncology and Obstetrics and Gynecology. According to data from OpenAlex, Matthew Boente has authored 54 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Reproductive Medicine, 17 papers in Oncology and 15 papers in Obstetrics and Gynecology. Recurrent topics in Matthew Boente's work include Ovarian cancer diagnosis and treatment (38 papers), Endometrial and Cervical Cancer Treatments (14 papers) and Intraperitoneal and Appendiceal Malignancies (10 papers). Matthew Boente is often cited by papers focused on Ovarian cancer diagnosis and treatment (38 papers), Endometrial and Cervical Cancer Treatments (14 papers) and Intraperitoneal and Appendiceal Malignancies (10 papers). Matthew Boente collaborates with scholars based in United States, France and Japan. Matthew Boente's co-authors include Bradley J. Monk, Mark F. Brady, Robert A. Burger, Howard D. Homesley, Jeffrey M. Fowler, Benjamin E. Greer, Michael A. Bookman, Helen Huang, Michael J. Birrer and Gini F. Fleming and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Matthew Boente

52 papers receiving 3.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

2011 1.6k citations Robert A. Burger, Mark F. Brady et al. New England Journal of Medicine profile →
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer

2016 250 citations John K. Chan, Mark F. Brady et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Matthew Boente United States	24	2.5k	1.5k	902	813	786	54	3.7k
Felix Hilpert Germany	29	2.5k 1.0×	1.6k 1.1×	762 0.8×	829 1.0×	1.0k 1.3×	172	3.9k
Stefania Cosio Italy	36	1.7k 0.7×	893 0.6×	729 0.8×	1.5k 1.8×	757 1.0×	118	3.4k
Carmen Tornos United States	38	2.0k 0.8×	916 0.6×	950 1.1×	1.9k 2.4×	621 0.8×	91	4.4k
Michael Teneriello United States	17	1.6k 0.6×	1.1k 0.7×	487 0.5×	512 0.6×	535 0.7×	33	2.3k
Deolinda Pereira Portugal	26	1.3k 0.5×	1.3k 0.9×	937 1.0×	266 0.3×	424 0.5×	86	2.8k
Kosei Hasegawa Japan	26	940 0.4×	1.4k 0.9×	678 0.8×	1.0k 1.2×	486 0.6×	179	3.0k
Shoji Kodama Japan	20	1.5k 0.6×	806 0.5×	474 0.5×	900 1.1×	473 0.6×	40	2.6k
Raji Ganesan United Kingdom	30	1.2k 0.5×	428 0.3×	547 0.6×	1.6k 1.9×	715 0.9×	112	3.1k
Andreas du Bois Germany	9	1.5k 0.6×	827 0.6×	328 0.4×	572 0.7×	819 1.0×	18	2.1k
Ruth Perets Israel	18	613 0.2×	1.3k 0.9×	914 1.0×	394 0.5×	414 0.5×	61	2.7k

Countries citing papers authored by Matthew Boente

Since Specialization

Citations

This map shows the geographic impact of Matthew Boente's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Boente with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Boente more than expected).

Fields of papers citing papers by Matthew Boente

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew Boente. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Boente. The network helps show where Matthew Boente may publish in the future.

Co-authorship network of co-authors of Matthew Boente

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew Boente. A scholar is included among the top collaborators of Matthew Boente based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew Boente. Matthew Boente is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Parra, Alberto, Elena Sotelo, I. Taboada, et al.. (2025). Large-scale randomized double-blind field clinical trial for safety and efficacy assessment of the DNA vaccine Neoleish against canine leishmaniasis. PLoS neglected tropical diseases. 19(11). e0012707–e0012707.

Boente, Matthew, et al.. (2024). Gynecological Cancers. Elsevier eBooks. 18. 371–398.

Gruenigen, Vivian E. von, Helen Huang, David Cella, et al.. (2018). Quality of life, symptoms and care needs in patients with persistent or recurrent platinum-resistant ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology. 150(1). 119–126. 13 indexed citations

Chan, John K., Mark F. Brady, Richard T. Penson, et al.. (2016). Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. New England Journal of Medicine. 374(8). 738–748. 250 indexed citations breakdown →

Burger, Robert A., Mark F. Brady, Michael A. Bookman, et al.. (2012). Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer. Obstetrical & Gynecological Survey. 67(5). 289–290. 197 indexed citations

Monk, Bradley J., Helen Huang, Robert A. Burger, et al.. (2012). Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: A Gynecologic Oncology Group Study. Gynecologic Oncology. 128(3). 573–578. 49 indexed citations

Geller, Melissa A., Joseph J. Ivy, Rahel Ghebre, et al.. (2011). A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a “Sandwich” method for stage III, IV, and recurrent endometrial cancer. Gynecologic Oncology. 121(1). 112–117. 46 indexed citations

Monk, B.J., Hsin-Hui Huang, Robert A. Burger, et al.. (2011). Quality of Life Outcomes of a Randomized, Placebo-Controlled Trial of Bevacizumab in the Front-Line Treatment of Ovarian Cancer: a Gynecologic Oncology Group Study. European Journal of Cancer. 47. 12–12. 2 indexed citations

Dusenbery, Kathryn E., Roger A. Potish, Douglas G. Gold, & Matthew Boente. (2005). Utility and limitations of abdominal radiotherapy in the management of endometrial carcinomas. Gynecologic Oncology. 96(3). 635–642. 4 indexed citations

10.

Dusenbery, Kathryn E., et al.. (2004). Twenty-five year outcome of sequential abdominal radiotherapy and melphalan:implications for future management of epithelial carcinoma of the ovary. Gynecologic Oncology. 96(2). 307–313. 11 indexed citations

11.

Downs, Levi S., Patricia L. Judson, Peter A. Argenta, Linda F. Carson, & Matthew Boente. (2004). A phase I study of ifosfamide, paclitaxel, and carboplatin in advanced and recurrent cervical cancer. Gynecologic Oncology. 95(2). 347–351. 4 indexed citations

12.

Bradley, William H., Matthew Boente, Doris Brooker, et al.. (2004). Hysteroscopy and Cytology in Endometrial Cancer. Obstetrics and Gynecology. 104(5, Part 1). 1030–1033. 45 indexed citations

13.

Judson, Patricia L., Amy L. Jonson, Pamela J. Paley, et al.. (2004). A prospective, randomized study analyzing sartorius transposition following inguinal–femoral lymphadenectomy. Gynecologic Oncology. 95(1). 226–230. 59 indexed citations

14.

Geller, Melissa A., Peter A. Argenta, William H. Bradley, et al.. (2004). Treatment and recurrence patterns in endometrial stromal sarcomas and the relation to c-kit expression. Gynecologic Oncology. 95(3). 632–636. 47 indexed citations

15.

Boente, Matthew, Andrew Berchuck, Regina S. Whitaker, et al.. (1998). Suppression of Diacylglycerol Levels by Antibodies Reactive with the c-erbB-2 (HER-2/neu) Gene Product p185c-erbB-2in Breast and Ovarian Cancer Cell Lines. Gynecologic Oncology. 70(1). 49–55. 4 indexed citations

16.

Boente, Matthew, et al.. (1995). Recurrence patterns and complications in endometrial adenocarcinoma with cervical involvement. Annals of Surgical Oncology. 2(2). 138–144. 20 indexed citations

17.

Schilder, Russell J., et al.. (1995). The management of early ovarian cancer.. PubMed. 9(2). 171–82; discussion 185. 10 indexed citations

18.

Xu, Fengji, Ruth Lupu, Gustavo C. Rodriguez, et al.. (1993). Antibody‐induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c‐erbb‐2 (her‐2/neu) gene product p185. International Journal of Cancer. 53(3). 401–408. 53 indexed citations

19.

Berchuck, Andrew, Matthew Boente, B. J. Kerns, et al.. (1992). Ploidy analysis of epithelial ovarian cancers using image cytometry. Gynecologic Oncology. 44(1). 61–65. 20 indexed citations

20.

Boente, Matthew, Andrew Berchuck, Gustavo C. Rodriguez, et al.. (1992). The effect of interferon gamma on epidermal growth factor receptor expression in normal and malignant ovarian epithelial cells. American Journal of Obstetrics and Gynecology. 167(6). 1877–1882. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact